Generupt is an Australian health technology company building the infrastructure for next-generation medicine. From AI-powered therapy development to accessible digital health platforms, we're transforming how rare diseases are treated and healthcare is delivered globally.
Target Diseases
Powered HTA
Reach
Building the complete ecosystem for gene therapy development, assessment, and patient access in Australia and beyond.
Developing curative treatments for rare CNS disorders including SPG50, Sanfilippo syndrome, and Batten disease through novel AAV vector platforms.
Our intelligent Health Technology Assessment engine evaluates cost-effectiveness, models outcomes, and accelerates reimbursement pathways for novel therapies.
Digital health platforms that enable healthcare professionals worldwide to support their communities of origin, bringing quality care to underserved regions.
An integrated platform spanning therapy development, health economics, and patient care.
Next-generation AAV vector systems designed for CNS delivery, targeting rare monogenic diseases in children.
AI-powered health technology assessment tools that accelerate market access for innovative therapies.
Enabling international medical graduates and healthcare professionals to deliver care to their home communities through innovative digital solutions.
Rapid diagnostic solutions designed for integration with telemedicine workflows, enabling faster clinical decisions in remote settings.
Targeting high-burden monogenic CNS disorders with profound unmet medical needs.
AP4M1 mutation
Ultra-rare motor neuron disease
MPS III (A-D)
1 in 70,000 incidence
CLN1-8 mutations
1 in 100,000 incidence
Leukodystrophies
Early-onset neurodegeneration
ATM gene defects
Progressive neurological disorder
Epileptic encephalopathy
Precision gene intervention
Generupt Pty Ltd is an Australian health technology company registered in Victoria, building the infrastructure for next-generation medicine with global reach.
Our approach is unique: we combine cutting-edge gene therapy research with AI-powered health economics tools and revenue-generating digital health platforms. This integrated model allows us to pursue our mission of curing rare diseases while building a sustainable business.
We work closely with Australia-based international medical graduates (IMGs) who are passionate about giving back to their communities. Our technology enables doctors from different parts of the world to continue supporting healthcare delivery in their countries of origin, bridging the gap between global expertise and local needs.
Victoria, Australia
Global Impact
Rare Disease Focus
AI-Powered
Interested in learning more about our work?
Victoria, Australia